SPONSORED / 7 MIN READ

Watch Out Elon Musk…
Little-Known Brain Stimulation Company Reports 1,868% Surge in Product Revenue Following FDA Submission…(28)(22)

And with one insider’s recent purchase of over 50,000 shares of NeuroOne Medical Technologies Corporation (NASDAQ: NMTC), now may be the perfect time to pay close attention. (32)

IMG-RIGHT-HEADER-DESKTOP-NMTC

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC)

7 Reasons Why Neuroone Medical Technologies Corp (NMTC) Could Be Poised For Significant Upside Potential ahead of 2024.

Recent FDA Submission:

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) recently made significant progress with its OneRF™ Ablation System, a groundbreaking technology that has the potential to transform neurosurgery. The submission of a 510(k) application to the U.S. Food and Drug Administration (FDA) for the OneRF™ Ablation System represents a major milestone for the company. (22)

Remarkable Revenue Surge:

In the world of medical technology, innovation often walks hand in hand with financial growth. NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) recently reported fiscal third-quarter 2023 financial results have drawn attention, particularly due to a substantial 1,868.75% increase in product revenue. This surge marks a significant milestone in NeuroOne's journey to revolutionize surgical care for patients suffering from neurological disorders. (28)

IMG-NUMBER-3

Insider Buying:

Insider acquisitions often offer valuable insights into a company's fundamental health and future outlook. On September 13, 2023, Ronald Mcclurg, the Chief Financial Officer (CFO) of NeuroOne Medical Technologies Corp (NASDAQ: NMTC), made a substantial insider purchase, acquiring 50,900 shares of the company's stock. This significant move could capture the attention of active market participants and analysts, pointing to a strong vote of confidence in the company's trajectory. (32)

Disruptive Technologies:

NeuroOne's patented technologies have the potential to disrupt the medical device industry, particularly in the field of neurology. The company's OneRF® Ablation System and Evo® Depth Electrode have the potential to revolutionize the way brain tumors and seizures are treated. (5)

IMG-NUMBER-5

Market Opportunity:

The market for neurostimulation devices is expected to reach $23.9 billion worldwide by 2030, with potential applications for Parkinson's Disease, Epilepsy, Essential Tremors, and other neurological conditions.(18) NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) estimates the current brain ablation market to be at least $100 million worldwide, with considerable growth opportunities driven by large patient populations with unmet clinical needs. (22)

IMG-NUMBER-6

Collaboration Deals:

In the fast-evolving landscape of medical technology, few companies have made as significant a mark as NeuroOne Medical Technologies Corporation (Nasdaq: NMTC). A recent financial report from the company has turned heads in the industry, particularly due to an astonishing 24,233% increase in collaboration revenue. This remarkable surge underscores NeuroOne's successful partnership with Zimmer Biomet and signals a bright future for the company in the realm of neurological healthcare. (28)

Strong Management Team & Advisory Board:

The company's advisory board is made up of leading neurosurgeons and anesthesiologists from prestigious institutions such as Mayo Clinic, Duke University Medical Center, and Emory University. NeuroOne Medical Technologies Corporation (Nasdaq: NMTC)'s management team has decades of experience in the medical device industry, with a track record of success in product development, marketing, and business development. (5)

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC)

Watch Out Elon Musk: NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) Makes Bold Move with FDA Application Submission for First Known sEEG-Guided RF System(23)(24)

Image Source (24)

Neuralink, the neurotech startup co-founded by Elon Musk, has made a significant breakthrough in its mission to develop brain implants with the announcement of FDA approval for its first in-human clinical study. This approval marks an important milestone for the company as it aims to help patients suffering from severe paralysis regain their ability to communicate by controlling external technologies using neural signals. (24)

The brain implant being developed by Neuralink, known as the Link, has the potential to revolutionize the lives of individuals with conditions like ALS. By harnessing neural signals, patients could regain the ability to communicate with their loved ones through the control of cursors and typing using their minds. (24)

In a tweet, Neuralink expressed gratitude for the collaborative effort between their team and the FDA, highlighting the importance of this achievement as an initial step toward helping many people. However, the specific details of the approved trial have not been disclosed, and patient recruitment is yet to begin.

Neuralink operates within the emerging field of brain-computer interfaces (BCIs), which involve decoding brain signals and translating them into commands for external devices. With Elon Musk’s involvement and the prominence of his other ventures, such as Tesla, SpaceX, and Twitter, Neuralink has gained significant attention within the BCI industry. (24)

While BCI technology has been under study for decades, receiving FDA approval for a commercial medical device is a rigorous process that involves extensive testing and data collection. So far, no BCI company has obtained the FDA’s final seal of approval. However, Neuralink’s FDA approval for an in-human study brings them closer to their goal of bringing their technology to the market. (24)

Neuralink’s BCI system requires patients to undergo invasive brain surgery, with the Link implant serving as the core component. The implant, a small circular device, processes and translates neural signals, which are detected by thin, flexible threads inserted directly into the brain tissue. (24)

Patients equipped with Neuralink devices will be able to control external devices such as mice and keyboards through a Bluetooth connection using the Neuralink app. (24)

The FDA’s approval of Neuralink’s in-human study comes after the company faced several challenges. In February, the U.S. Department of Transportation initiated an investigation into Neuralink’s alleged unsafe packaging and transportation of contaminated hardware. Additionally, reports surfaced in March that the FDA had initially rejected Neuralink’s application for human trials, highlighting numerous concerns that needed to be addressed. (24)

Neuralink has also faced criticism from activist groups regarding its treatment of animals during experiments. The Physicians Committee for Responsible Medicine (PCRM), an organization advocating against animal testing, has urged Musk to disclose details about the experiments involving monkeys, which allegedly resulted in severe health issues and death. (24)

Beyond assisting patients with paralysis, experts believe that BCIs hold potential in treating other conditions such as blindness and mental illness. Musk himself has expressed a broader vision for Neuralink to explore these future applications, including potential uses for healthy individuals. (24)

As Neuralink continues to make strides in the field of brain implants and BCIs, it is certainly a company worth keeping an eye on. With its innovative technology and the vision of Elon Musk, Neuralink has the potential to transform the way we interface with and understand the human brain. (24)

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) is another company that warrants attention in the field of medical technology. While Neuralink focuses on brain implants and BCIs, NeuroOne is dedicated to improving surgical care options and outcomes for patients with neurological disorders. (23)

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) has recently made significant progress with its OneRF™ Ablation System, a groundbreaking technology that has the potential to transform neurosurgery. The system is the first known stereoelectroencephalography (sEEG)-guided radio frequency (RF) system capable of recording and ablating nervous tissue, offering the added benefit of temperature control. By utilizing already implanted sEEG electrodes to record brain activity, the system can precisely ablate nervous tissue when connected to a proprietary RF generator. (23)

IMG-2-NMTC

Image Source (25)

The submission of a 510(k) application to the U.S. Food and Drug Administration (FDA) for the OneRF™ Ablation System represents a major milestone for NeuroOne Medical Technologies Corporation (NASDAQ: NMTC). If the application is cleared by the FDA, the company will be one step closer to bringing this innovative RF ablation system to the market. The OneRF™ Ablation System combines diagnostic and therapeutic capabilities, providing clinicians with greater control over temperature management during the ablation process. This not only offers a safer clinical option for patients but also has the potential to reduce the number of invasive procedures and hospital stays, resulting in lower costs. (23)

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) estimates that the current brain ablation market is valued at least $100 million worldwide, with significant growth potential due to the large addressable patient populations with unmet clinical needs. With the groundbreaking nature of the OneRF™ Ablation System and its potential to revolutionize neurosurgical procedures, NeuroOne is a company to watch closely. (23)

Dave Rosa, the CEO of NeuroOne Medical Technologies Corporation (NASDAQ: NMTC), expressed his excitement and pride in the achievement of submitting the 510(k) application. He emphasized the significance of this milestone as it represents the first known FDA submission of an sEEG electrode intended for both recording brain activity and ablating nervous tissue. Rosa also highlighted the potential applications of the system beyond brain tissue ablation, indicating a broader opportunity for NeuroOne than initially anticipated. (23)

As NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) awaits initial feedback from the FDA regarding the application, industry observers and stakeholders should keep a close eye on the company’s progress. With its commitment to improving surgical care options and its innovative OneRF™ Ablation System, NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) has the potential to make a significant impact in the field of neurology and neurosurgery, benefiting patients and advancing medical technology. (23)

Could NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) Make Another Potential 278% Move Like it Did Last Summer? (2)

Image Source (30)
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) is a pioneering medical technology company dedicated to enhancing surgical care options and improving outcomes for patients afflicted by neurological disorders. As of June 30, 2023, the company has reached significant milestones and reported promising financial results for the fiscal third quarter of 2023, demonstrating its commitment to innovation and growth in the field of neurological healthcare. (29)

Financial Highlights (29)

In the third quarter of 2023, NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) achieved remarkable financial results, with a notable surge in product revenue. The company reported product revenue of $630,000, representing a substantial increase compared to the $32,000 reported in the same quarter of 2022. For the first nine months of fiscal 2023, product revenue reached $1.2 million, a significant improvement from the $102,000 reported for the same period in fiscal 2022.

Collaboration revenue also saw a remarkable upswing, reaching $1.46 million in the first nine months of fiscal 2023, compared to a mere $6,000 in the same period the previous year. This revenue was generated through the Zimmer Development Agreement and includes exclusivity and milestone fee payments.

Importantly, NeuroOne anticipates a reduction in operating cash burn with the completion of the development of the OneRF™ Ablation System, a key milestone slated for fiscal Q4 2023.

Innovations and Achievements (29)

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) has made substantial progress in its various product lines and initiatives:

Evo® sEEG: The company successfully completed a limited launch of Evo sEEG electrode systems at target centers by the end of July, with a full launch in partnership with Zimmer Biomet expected by the end of the fiscal fourth quarter. Positive user feedback has been received, and the initiation of new sites is expected to gain momentum in the upcoming quarter.

OneRF™ Ablation: NeuroOne submitted a 510(k) application to the FDA for the OneRF Ablation System on June 8th, and a poster presentation on a preclinical study of the system was made at the Neurological Disorders Summit (NDS 2023) in Italy. Feedback from the FDA on the 510(k) submission has been received, reinforcing the company’s confidence in its timelines.

Spinal Cord Stimulation Program: The company completed a 28-day animal implantation of its thin-film spinal cord stimulation paddle electrodes without any adverse events or neurological complications. Additionally, a non-provisional patent was filed for a novel conformable thin-film paddle lead for spinal cord placement.

D-rug Delivery Program: NeuroOne successfully completed proof-of-concept testing for drug delivery into the brain using a small animal model at the Mayo Clinic in Rochester, Minnesota, showcasing the potential of this innovative program.

CEO’s Perspective (29)

Dave Rosa, CEO of NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), expressed optimism about the company’s achievements and future prospects, stating, “The Company continues to execute on a number of commercial, development, and financing objectives.” He highlighted the expansion of the commercial launch of the Evo sEEG electrode with Zimmer Biomet and the encouraging feedback from the FDA regarding the OneRF Ablation System. Rosa also emphasized the potential of the drug delivery system currently in development and the successful capital raises to support NeuroOne’s strategic plan.

Upcoming Milestones (29)

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) is poised for further growth, with several key milestones on the horizon:

Evo sEEG: The company plans to fully launch the Evo sEEG system with Zimmer Biomet and expand sales training for the sEEG product line to Zimmer personnel.

OneRF Ablation: A poster presentation is scheduled for the Congress of Neurological Surgeons (CNS) Meeting in September, and component orders for the OneRF ablation system for future commercialization are set to commence.

Spinal Cord Stimulation Program: Testing of an implantable pulse generator (IPG) for fluid ingress will be completed, and percutaneous placement of a paddle electrode in a human cadaver model is planned.

Drug Delivery Program: NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) aims to define product requirements for the drug delivery system for both clinical and research use in the biotech and pharma industry, along with completing large animal feasibility studies for drug delivery into the brain.

Financial Overview (29)

As of June 30, 2023, the company had cash and cash equivalents of $3.1 million and no outstanding debt. NeuroOne raised gross proceeds of $6.0 million through a public offering and an additional $2.5 million through an ATM facility, reflecting a strong financial position.

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC)’s strong fiscal third-quarter 2023 results and ongoing advancements in neurological healthcare innovations underscore its commitment to improving patient outcomes in the realm of neurological disorders. With a robust product portfolio, promising developments, and a solid financial position, NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) is well-positioned to make a significant impact in the field of neurology and continue its trajectory of growth and success.

SUBSCRIBE TO OUR NEWSLETTER
FOR MUST READ REPORTS & NEWS.

Getting the Right News Before Everyone Else Does, is FREE…

Terms | Privacy Policy Message and data rates may apply. Reply STOP keyword to be opted out of the program. Reply Help for Help. We will never sell or share to third parties. For informational purposes only.

Could the NeuroOne Medical Technologies Corporation (Nasdaq: NMTC)’s Chart Be Displaying Over 229% in Upside Potential?

Chart Source (31)
Look at NeuroOne Medical Technologies Corporation (NASDAQ: NMTC)’s daily chart above and do a little technical analysis using StockCharts.com and Barchart.com.

Check out the following averages as of 10/9/2023:
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) is demonstrating significant upside potential with a 52-week range of $.80 to $2.87. (2)

According to Barchart.com, NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) opened at $.8701 on 10/9/2023 indicating an upside potential of over 229% if shares were to reach back to their 52-week high of $2.87 set back on 12/9/2022. (2)

Now we must note that no such return to previous highs is certain, but the potential upside is too high not to note from current levels.

And if you’re still deep in thought considering if it’s possible for (NMTC) to have a potential 229% upside, then you should consider this…

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) has less than 23 million shares in its public float according to MarketWatch.com. (27)

Market participants typically consider a float of 10-to-20 million shares as a low float. Some larger corporations have very high floats in the billions. (8) A low-float stock can make significant moves due to volatility from so few shares being available(8), so this could be an interesting situation to watch closely.

…And companies with a low float frequently have a large portion of their equity held by controlling stakeholders such as directors and employees, which leaves only a tiny percentage of shares available for public trading. (8)

That limited supply can cause dramatic swings if demand changes quickly. (8)

Remember! NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) has less than 23 million shares in its public float and according to MarketWatch.com, and insiders already own 7.73% of them, as of 10/9/2023, according to FinViz.com. (3)

In fact, just last month, on September 13, 2023, Ronald Mcclurg, the Chief Financial Officer (CFO) of NeuroOne Medical Technologies Corp (NASDAQ:NMTC), made a significant insider purchase of 50,900 shares of the company’s stock. This move has caught the attention of investors and market analysts alike, as insider buying often signals confidence in the company’s future prospects. (32)

With a market cap of just under $22 million according to MarketWatch.com as of 10/9/2023, (9) there could be significant upside potential for those who are willing to research this emerging medical device company.

Which is why things could get very interesting and also why you need to start your research on NeuroOne Medical Technologies Corporation (NASDAQ: NMTC).

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC)

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) Receives FDA Clearance. (1)

2

Image Source (6)

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) has recently received FDA clearance for its Evo® sEEG electrode, marking a major milestone for the company. The Evo® sEEG electrode is a thin-film, high-definition electrode that provides clear and accurate recordings of brain activity during neurosurgical procedures.(5)
The Evo® sEEG electrode is a disruptive technology that has the potential to transform the field of neurology. The electrode is designed to be used in conjunction with the company’s OnePass™ technology, which allows for the placement of multiple electrodes in a single pass, reducing the time and complexity of the surgical procedure.
This technology has the potential to make neurosurgery more efficient and effective, improving patient outcomes and reducing healthcare costs. (5) The clearance of the Evo® sEEG electrode is a significant achievement for NeuroOne, as it is the company’s first FDA-cleared product. The company is now in a position to begin commercializing the electrode.

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC)

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC)’s Patented Technologies have the Potential to Disrupt the Medical Device Industry, Particularly in the Field of Neurology. (5)

3

Image Source (6)

NeuroOne’s patented technologies have the potential to disrupt the medical device industry, particularly in the field of neurology. The company’s OneRF® Ablation System and Evo® Depth Electrode have the potential to revolutionize the way brain tumors and seizures are treated. (5)

The OneRF® Ablation System is a unique technology that combines radiofrequency energy and a proprietary fluid delivery system to create a localized thermal ablation of brain tissue.(5)

This targeted approach is intended to reduce the risk of collateral damage to surrounding healthy tissue, which can occur with traditional surgical methods. The OneRF® Ablation System has the potential to offer patients a minimally invasive treatment option that could reduce complications and improve outcomes. (10)

Image Source (11)

The Evo® Depth Electrode is a flexible electrode that is used for intracranial EEG (iEEG) recordings in epilepsy patients. The Evo® Depth Electrode was designed with an innovative design that includes multiple flexible arms, each with four contact points, allowing for a more precise and accurate mapping of brain activity. This technology could help to identify seizure foci with greater accuracy, improving the chances of successful surgical outcomes and reducing the risk of complications.(12)

NeuroOne’s innovative technologies could potentially revolutionize the way neurological conditions are treated, offering patients safer, less invasive treatment options with better outcomes. The company’s technology also has the potential to reduce healthcare costs by shortening hospital stays and reducing the need for repeat procedures. (5)

NeuroOne’s disruptive technologies have the potential to significantly improve patient outcomes while simultaneously transforming the medical device industry.

Want to Learn More ?

Click the button to get started

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC)

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC)’s Platform Technology has the Potential for Multiple Applications, Making it a Versatile Player in the Medical Device Industry. (5)

5

Image Source (13)

The company’s technologies can be used in spinal cord and deep brain stimulation, as well as targeted stimulation for movement, psychiatric, and cognitive disorders. (5)

The potential applications for NeuroOne’s technology are vast. In spinal cord stimulation, the technology could be used to treat chronic pain, which affects millions of people worldwide. Deep brain stimulation has been shown to be effective in treating Parkinson’s disease, essential tremors, and dystonia, with the potential for additional applications such as depression and obsessive-compulsive disorder.

Targeted stimulation for movement disorders could be a game-changer in the treatment of neurological disorders. This technology has the potential to enable precise and targeted stimulation of specific regions of the brain, reducing the side effects associated with current treatments.(5)

The platform technology’s versatility also has implications for psychiatric and cognitive disorders. Neurostimulation has been shown to be effective in treating depression, anxiety, and substance abuse disorders. By leveraging its platform technology, NeuroOne can potentially develop therapies for these conditions that are more effective and with fewer side effects than current treatments.

NeuroOne’s platform technology has the potential to address unmet medical needs in a variety of neurological and psychiatric conditions, making it a promising player in the medical device industry.(5)

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC)

The Market for Neurostimulation Devices is expected to Reach$23.9 Billion Worldwide by 2030. (18)

Image Source (18)

The market for neurostimulation devices is expected to reach $23.9 billion worldwide by 2030, with potential applications for Parkinson’s Disease, Epilepsy, Essential Tremors, and other neurological conditions.(18) The growing demand for neurostimulation devices can be attributed to the rising incidence of neurological disorders, an aging population, and advancements in technology. (14)

Parkinson’s Disease, which affects over 10 million people worldwide, is a progressive disorder that impairs movement and coordination. Neurostimulation devices, such as deep brain stimulation (DBS), have been shown to be effective in treating the symptoms of Parkinson’s Disease. (15)

Epilepsy, which affects over 50 million people worldwide, is a neurological disorder characterized by recurrent seizures. Neurostimulation devices, such as vagus nerve stimulation (VNS), have been shown to reduce the frequency and severity of seizures in patients with epilepsy. (16)

Essential Tremors, which affect over 7 million people in the US alone, are involuntary movements that can affect the hands, head, and voice. Neurostimulation devices, such as deep brain stimulation (DBS), have been shown to be effective in reducing the symptoms of Essential Tremors. (17)

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) is also advancing a pipeline of therapeutic electrode technologies for brain tissue ablation and chronic stimulation use for DBS (deep brain stimulation) and spinal cord stimulation for chronic back pain. These therapeutic electrode technologies represent addressable markets valued between $500 million and $6 billion. (19)

With the potential for NeuroOne’s platform technology to be applied in multiple neurological conditions, the company is well-positioned to capture a significant share of the growing neurostimulation device market. Additionally, the company’s disruptive technologies, such as the OneRF® Ablation System and Evo® Depth Electrode, have the potential to revolutionize the way neurological conditions are treated, further increasing the company’s potential for growth in the neurostimulation device market. (5)

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC)

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC)'s disruptive technologies and platform potential make the company an attractive partner for larger medical device companies looking to expand their product offerings in the neurology space. (5)

Image Source (20)

In 2022, the top 10 medical device companies in the world totaled over $188 billion in revenue. (20)

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC)’s disruptive technologies and platform potential make the company an attractive partner for larger medical device companies looking to expand their product offerings in the neurology space. The company’s strategy to access the ablation market through additional partnerships leveraging the resources of commercial med tech companies is a testament to its potential for successful collaborations. (5)

Zimmer Biomet, one of the largest medical device companies in the world, has rights of first negotiation with NeuroOne. This partnership provides NeuroOne with the resources and expertise of a well-established company to help bring its products to market and expand its reach. (5)

NeuroOne’s electrode technology has potential applications in a variety of neurological conditions, including epilepsy, Parkinson’s disease, and chronic pain, presenting an opportunity for partnerships with companies developing treatments in these areas. The company’s innovative thin-film electrode technology offers a competitive advantage over current electrode technology and may be of interest to companies looking to differentiate themselves in the market. (5)

NeuroOne’s potential partnerships with larger medical device companies could provide the company with access to greater resources, expertise, and distribution channels, enabling it to accelerate its growth and expand its reach.

NeuroOne’s potential for successful partnerships in the neurology space represents a significant growth opportunity for the company.

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC)

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC)'s advisory board is made up of leading neurosurgeons and anesthesiologists from prestigious institutions. (5)

Image Source (21)

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC)’s strong advisory board is made up of leading neurosurgeons and anesthesiologists from prestigious institutions such as Mayo Clinic, Duke University Medical Center, and Emory University.(5)The expertise and experience of the advisory board members are critical to NeuroOne’s success in developing and commercializing innovative electrode technologies for neurological conditions.

The advisory board’s members provide NeuroOne with valuable insights and guidance in the areas of product development, clinical research, and regulatory affairs. Their knowledge and experience in the field of neurology help the company to identify unmet needs in the market and develop solutions that address those needs.

The advisory board members serve as key opinion leaders in the neurology space, helping to raise awareness of NeuroOne’s products and technologies and promoting the adoption of these products by their peers in the medical community.(5)

NeuroOne’s strong advisory board represents a significant asset for the company, providing it with the expertise and guidance needed to successfully develop and commercialize innovative electrode technologies for the treatment of neurological conditions.

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC)

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC)’s CFO Ronald Mcclurg's Insider Purchase Signals Confidence in Future Prospects… (32)

Image Source (33)
In the world of financial markets, insider acquisitions often offer valuable insights into a company’s fundamental health and future outlook. On September 13, 2023, Ronald Mcclurg, the Chief Financial Officer (CFO) of NeuroOne Medical Technologies Corp (NASDAQ: NMTC), made a substantial insider purchase, acquiring 50,900 shares of the company’s stock. This significant move has captured the attention of investors and market analysts, pointing to a strong vote of confidence in the company’s trajectory. (32)

Understanding the Significance (32)

Ronald Mcclurg’s decision to acquire 50,900 shares of NeuroOne Medical Technologies Corp (NASDAQ: NMTC) stock is noteworthy due to his position as the Chief Financial Officer. As a seasoned financial executive with extensive experience in the healthcare industry, Mcclurg holds a key role in shaping the company’s financial strategy and operations. His investment in the company’s shares underlines his belief in NeuroOne’s growth and development prospects.

NeuroOne Medical Technologies Corp (NASDAQ: NMTC) is dedicated to advancing surgical care options and enhancing outcomes for patients suffering from neurological disorders. The company specializes in the development and commercialization of innovative solutions that have the potential to benefit millions of patients grappling with common neurological conditions such as epilepsy, Parkinson’s disease, and chronic pain resulting from failed back surgeries. (32)

Over the past year, Mcclurg has consistently demonstrated his confidence in NeuroOne by acquiring a total of 50,900 shares, without any corresponding sales. This pattern of insider buying highlights a strong conviction in the company’s future potential and its mission to make a meaningful impact in the field of neurological healthcare. (32)

A Positive Trend of Insider Buys (32)

When examining the insider transaction history of NeuroOne Medical Technologies Corp (NASDAQ: NMTC), a positive trend emerges. Over the past year, there have been more instances of insider buying than selling. This trend carries significance for investors, as it suggests that individuals with an intimate understanding of the company’s operations perceive genuine value in its stock.

At the time of Mcclurg’s recent insider purchase, NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) shares were trading at $0.98 each, resulting in a market capitalization of $23.919 million. While this market cap may appear relatively modest in the broader market context, it is crucial to recognize that Mcclurg’s investment represents a significant commitment to the company. (32)

The relationship between insider buying, insider selling, and stock prices can be intricate. However, it is generally recognized that substantial insider purchases, especially by high-ranking executives like CFO Ronald Mcclurg, often serve as a bullish signal. Insiders possess unique insights into a company’s operations and future prospects, and their willingness to invest personal funds in the company’s stock signifies their belief in its undervaluation or robust growth potential. (32)

In light of Ronald Mcclurg’s recent insider purchase, it appears that NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) is well-positioned to continue its journey of innovation and growth, with a firm foundation built on the confidence of those leading the charge. (32)

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC)

Meet the Management Team That’s Leading NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) Into 2023 and Beyond. (5)

9

Image Source (19)

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC)’s management team has decades of experience in the medical device industry, with a track record of success in product development, marketing, and business development.

dave

Dave Rosa - President and Chief Executive Officer

Meet Dave Rosa, a medical device industry expert with over three decades of experience, spanning a wide range of technologies and products. In addition to his CEO roles with early-stage medical device companies, Dave has held senior positions with leading companies, including C.R. Bard, Boston Scientific, and St. Jude Medical. Dave has been named as an inventor on multiple medical device patents, served on seven corporate boards, and raised $200M in capital markets. He holds an MBA from Duquesne University and a BS in Commerce and Engineering from Drexel University.

ron

Ron McClurg - Chief Financial Officer

Meet Ron McClurg, a financial leader with over 30 years of experience with private and public companies. Prior to joining NeuroOne, Ron was CFO of Incisive Surgical, a medical device manufacturer, and CFO and Treasurer of Wavecrest Corporation, a manufacturer of electronic test instruments. Ron has also held CFO positions with several publicly held companies, including Video Sentry Corporation, Insignia Systems, and Orthomet. He began his career in public accounting with Ernst & Young, where he earned his CPA certificate. Ron holds a Bachelor of Business Administration degree in Accounting from the University of Wisconsin Eau Claire.

steve

Steve Mertens - Chief Technology Officer

Meet Steve Mertens, a product development expert with a passion for innovation. Prior to joining NeuroOne, Steve was Senior Vice President of R&D and Operations at Nuvaira, a lung denervation company developing minimally invasive products for obstructive lung diseases. Before that, he was a Senior Vice President of Research and Development for Boston Scientific, where he guided a wide range of technologies through product development for the cardiology, electrophysiology, and peripheral vascular markets. Steve holds a Bachelor of Science degree in Chemical Engineering from the University of Minnesota and a master's degree in Business Administration from the University of St. Thomas.

mark

Mark Christianson - Co-Founder, Business Development Director, Medical Sales Liaison

Meet Mark Christianson, a seasoned executive with over 15 years of experience in sales, sales management, marketing, and project management with development-stage companies. Prior to NeuroOne, Mark held the positions of North American Sales Manager for Cortec Corporation, a manufacturer of specialty chemical products, and Regional Sales Manager for PMT Corporation, a leading manufacturer of products for neurosurgery, orthopedics, and plastic surgery. Mark holds an accounting degree from Augsburg College.

The management team’s expertise and experience in the medical device industry provide NeuroOne with the leadership and guidance needed to successfully develop and commercialize innovative electrode technologies for neurological conditions.

Overall, NeuroOne’s experienced management team is a key strength of the company and an important factor in its potential for long-term success.

Little-Known Brain Stimulation Company Reports 1,868% Surge in Product Revenue Following FDA Submission…(28)(22)

And with one insider’s recent purchase of over 50,000 shares of NeuroOne Medical Technologies Corporation (NASDAQ: NMTC), now may be the perfect time to pay close attention. (32)

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC)

7 Reasons Why Neuroone Medical Technologies Corp (NMTC) Could Be Poised For Significant Upside Potential ahead of 2024.

Recent FDA Submission:

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) recently made significant progress with its OneRF™ Ablation System, a groundbreaking technology that has the potential to transform neurosurgery. The submission of a 510(k) application to the U.S. Food and Drug Administration (FDA) for the OneRF™ Ablation System represents a major milestone for the company. (22)

Remarkable Revenue Surge:

In the world of medical technology, innovation often walks hand in hand with financial growth. NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) recently reported fiscal third-quarter 2023 financial results have drawn attention, particularly due to a substantial 1,868.75% increase in product revenue. This surge marks a significant milestone in NeuroOne's journey to revolutionize surgical care for patients suffering from neurological disorders. (28)

IMG-NUMBER-3

Insider Buying:

Insider acquisitions often offer valuable insights into a company's fundamental health and future outlook. On September 13, 2023, Ronald Mcclurg, the Chief Financial Officer (CFO) of NeuroOne Medical Technologies Corp (NASDAQ: NMTC), made a substantial insider purchase, acquiring 50,900 shares of the company's stock. This significant move could capture the attention of active market participants and analysts, pointing to a strong vote of confidence in the company's trajectory. (32)

Disruptive Technologies:

NeuroOne's patented technologies have the potential to disrupt the medical device industry, particularly in the field of neurology. The company's OneRF® Ablation System and Evo® Depth Electrode have the potential to revolutionize the way brain tumors and seizures are treated. (5)

IMG-NUMBER-5

Market Opportunity:

The market for neurostimulation devices is expected to reach $23.9 billion worldwide by 2030, with potential applications for Parkinson's Disease, Epilepsy, Essential Tremors, and other neurological conditions.(18) NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) estimates the current brain ablation market to be at least $100 million worldwide, with considerable growth opportunities driven by large patient populations with unmet clinical needs. (22)

IMG-NUMBER-6

Collaboration Deals:

In the fast-evolving landscape of medical technology, few companies have made as significant a mark as NeuroOne Medical Technologies Corporation (Nasdaq: NMTC). A recent financial report from the company has turned heads in the industry, particularly due to an astonishing 24,233% increase in collaboration revenue. This remarkable surge underscores NeuroOne's successful partnership with Zimmer Biomet and signals a bright future for the company in the realm of neurological healthcare. (28)

Strong Management Team & Advisory Board:

The company's advisory board is made up of leading neurosurgeons and anesthesiologists from prestigious institutions such as Mayo Clinic, Duke University Medical Center, and Emory University. NeuroOne Medical Technologies Corporation (Nasdaq: NMTC)'s management team has decades of experience in the medical device industry, with a track record of success in product development, marketing, and business development. (5)

Source 1: https://finance.yahoo.com/news/neuroone-reports-first-quarter-fiscal-210000438.html
Source 2: https://www.barchart.com/stocks/quotes/NMTC/price-history/historical
Source 3: https://finviz.com/quote.ashx?t=NMTC&p=d
Source 4: https://www.prnewswire.com/news-releases/neuroone-receives-fda-510k-clearance-to-market-its-evo-seeg-system-for-less-than-30-day-use-301658314.html
Source 5: https://storage.googleapis.com/neuroone-1156-4b1gd/NeuroOne-InvestorPresentation-Feb-2023.pdf
Source 6: https://stockcharts.com/h-sc/ui
Source 7: https://www.raps.org/RAPS/media/news-images/news-images/FDA-Logo.jpg
Source 8: https://www.sofi.com/learn/content/understanding-low-float-stocks/
Source 9: https://www.marketwatch.com/investing/stock/nmtc?mod=search_symbol
Source 10: https://parkinsonsnewstoday.com/news/neuroone-will-ask-fda-clear-rf-ablation-system-parkinsons-2023/
Source 11: https://biotuesdays.com/wp-content/uploads/2020/07/NeuroOne-Rolled-Electrode.jpg
Source 12: https://biotuesdays.com/2020/07/14/neuroone-developing-electrode-technology-to-treat-neurological-conditions/
Source 13: https://biotuesdays.com/wp-content/uploads/2020/07/Banner-NeuroOne-1024×512.jpg
Source 14: https://www.globenewswire.com/en/news-release/2022/07/11/2477549/0/en/Neurostimulation-Devices-Market-Size-is-projected-to-reach-USD-14-billion-by-2030-growing-at-a-CAGR-of-13-Straits-Research.html
Source 15: https://www.abbott.com/corpnewsroom/products-and-innovation/how-dbs-is-advancing-parkinsons-treatment.html
Source 16: https://www.who.int/news-room/fact-sheets/detail/epilepsy
Source 17: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4137360/
Source 18: https://www.precedenceresearch.com/neurostimulation-devices-market
Source 19: https://www.prnewswire.com/news-releases/neuroone-receives-fda-510k-clearance-to-market-its-evo-seeg-system-for-less-than-30-day-use-301658314.html
Source 20: https://www.breakingintodevice.com/blogs/medical-sales/top-medical-device-2022
Source 21: https://minitex.umn.edu/sites/default/files/styles/manual_crop_16_9/public/images/2021-11/Mayo-Clinic-Logo-2001.jpg?h=cd178615&itok=wiZRzcm2
Source 22: https://finance.yahoo.com/news/neuroone-submits-510-k-application-123500923.html
Source 23: https://www.cnbc.com/2023/05/25/elon-musks-neuralink-gets-fda-approval-for-in-human-study.html
Source 24: https://cdn.punchng.com/wp-content/uploads/2023/05/26220648/Is-Elon-Musks-Neuralink.jpg
Source 25: https://www.medicaldevice-network.com/wp-content/uploads/sites/23/2023/06/brain-activity.jpg
Source 26: https://schrts.co/wKFpmdgN
Source 27: https://www.marketwatch.com/investing/stock/nmtc?mod=search_symbol
Source 28: https://app.quotemedia.com/data/downloadFiling?type=HTML&webmasterId=500&ref=317688046
Source 29: https://finance.yahoo.com/news/neuroone-reports-third-quarter-fiscal-200000988.html
Source 30: https://mma.prnewswire.com/media/1357756/NeuroOne_Logo.jpg?p=facebook
Source 31: https://schrts.co/fxHVgghy
Source 32: https://finance.yahoo.com/news/insider-buying-cfo-ronald-mcclurg-050122479.html
Source 33: https://image.cnbcfm.com/api/v1/image/107060697-16524392856ED4-WEX-051322-InsiderBuying.jpg?v=1652439284

GET RED-HOT NEWS DELIVERED RIGHT TO YOUR INBOX.

Getting the Right News Before Everyone Else Does, is FREE…